All In Biotech

Drug Trial Radar · NCT05722782

Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics

The Investigation of the Efficacity and Safety of Oral Non Steroidal Anti Inflammatory (NSAI) Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Department for Renal Colics

Last checked: Nov 19, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jul 1, 2023

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Lead sponsor
University of MonastirAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Treatment with NSAI in renal colics has not been well investigated and there is no clear recommendations regarding this subject. The aim of this study is to determine if an oral NSAI treatment is beneficial in patients discharged for the emergency department after the first line treatment of a renal colic investigating the reccurence of pain, the reconsultation rates and the admissions.

Conditions

  • Renal Colic

Interventions

  • PiroxicamDrug

    Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment

  • AcetaminophenDrug

    Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment

  • PlaceboDrug

    Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacity of oral NSAITime frame: 07 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fattouma Bourguiba University Hospital

    Monastir, Tunisia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.